Introduction

Technological advances combined with improved understanding of the genetic basis of cancer has revolutionized the way we manage cancer. Utilizing patient’s particular genomic profile, clinicians can now assess the risk of hereditary cancer for the patient and patient’s family, as well as tailor the best treatment options.

BGI’s SENTIS™ Cancer+Discovery provides clinicians with one of the market’s most comprehensive and accurate Next Generation Sequencing (NGS) based testing solution for the identification of clinically actionable mutations, as well as discovery of novel variants with important function in cancer. Supporting both tissue sample and liquid biopsy, the panel offers whole exon coverage of 508 cancer-related genes and interrogates most common types of alterations including SNVs, indels, CNVs and fusions in solid tumors.

The Power of Knowing
BGI SENTIS™ Cancer+Discovery (Tissue/ctDNA)

Advantages

Comprehensive
- Whole exon coverage of 508 cancer-related genes, supporting most common types of genomic alterations including base substitutions, InDel, CNV and fusion
- Includes genes associated with both sporadic and hereditary cancers
- Provides interpretation on the therapeutic relevance in 100+ drugs, including targeted therapies (both approved and currently in clinical trial) and commonly used chemotherapies
- Includes 326 genes in cancer-related pathways for discovery of novel pathogenic variants

Flexible
- BGI SENTIS™ Cancer+Discovery (Tissue): fresh tissue, biopsy, FFPE, or DNA
- BGI SENTIS™ Cancer+Discovery (ctDNA): peripheral blood or DNA

High Performance
- Sensitivity/Specificity >99%*

Liquid biopsy version allows genetic profiling in situations where tissue is not available or continuous monitoring of tumor molecular profile is required.

* See technical information for details.
The Power of Knowing
BGI SENTIS™ Cancer+Discovery (Tissue/ctDNA)

Gene Panel Overview

508 Genes

119 Drug Target Genes

63 Hereditary Cancer Genes

326 Pathway Related Genes

Interpretation for >100 drugs

Evaluate the risk for hereditary cancer

Discover new drug target and drug resistant genes

Technical Information

<table>
<thead>
<tr>
<th>ITEM</th>
<th>CATALOG NO.</th>
</tr>
</thead>
<tbody>
<tr>
<td>BGI SENTIS™ Cancer+Discovery (Tissue)</td>
<td>DX0643</td>
</tr>
<tr>
<td>BGI SENTIS™ Cancer+Discovery (ctDNA)</td>
<td>DX0644</td>
</tr>
</tbody>
</table>

Sample Requirements

BGI SENTIS™ Targeted Therapy (Tissue)
- >60mg tissue or 15 FFPE 10mm*10mm (5-10µm) sections or ≥3 samplings of biopsy or ≥1µg good quality, tumor DNA;
- 5mL of peripheral blood

BGI SENTIS™ Targeted Therapy (ctDNA)
- ≥10mL of peripheral blood (separated plasma and formed elements) or ≥8mL of peripheral blood collected in Streck Cell-Free DNA BCT® tube

Turnaround time

10 working days (from sample arriving at BGI lab to report)

Workflow

Counselling and Consent

Sample Collection

DNA Extraction and QC

Targeted Capture and NGS

Data Analysis and Interpretation

Report Ready

Genetic Counselling

Contact your local BGI representative for more information or email info@bgi-international.com.

More information can also be found on our website.

www.bgi.com/global/

Copyright© 2017 BGI. Copyright© 2017 BGI. The BGI logo and SENTIS logo are trademarks of BGI. All rights reserved.
Published: June 2017, version 1.0
For Research Use Only. Not for use in diagnostic procedures.
Testing services not currently available in the United States of America. Please contact a representative for regional availability.